Beta-thalassemia (B-thal) - Epidemiology Forecast - 2032

DelveInsight’s "Beta Thalassemia – Epidemiology Forecast–2032" report delivers an in-depth understanding of Beta thalassemia historical and forecasted epidemiology in the United States and EU5 (Germany, Spain, Italy, France, and the United Kingdom).
Beta Thalassemia Disease Understanding
Beta Thalassemia (β-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis.
Beta Thalassemia Epidemiology
The Beta Thalassemia epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed prevalence, diagnosed Beta thalassemia by patient type, trends, and assumptions.
Key Findings
The total prevalent cases of Beta Thalassemia patients are increasing in 6MM during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted Beta Thalassemia symptoms epidemiology segmented as the Total prevalent cases of Beta Thalassemia minor, the Diagnosed prevalence of Beta thalassemia, and Diagnosed Beta Thalassemia patients by disease type. The report includes the prevalent scenario of Beta Thalassemia symptoms in 6MM covering the United States and EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) from 2019 to 2032.
Country-wise Beta Thalassemia Epidemiology
The epidemiology segment also provides the Beta Thalassemia epidemiology data and findings across the United States and EU5 (Germany, France, Italy, Spain, and the United Kingdom).
The prevalent cases of Beta Thalassemia minor associated in 6MM countries were 12,536 in 2020.
• As per the estimates, the United States has the second-largest prevalent population of Beta Thalassemia
• Among the EU5 countries, Italy had the highest prevalent cases of Beta Thalassemia, followed by Germany, the UK, and France. On the other hand, Spain had the lowest prevalent cases with 275 cases in 2020.
Scope of the Report
• The Beta Thalassemia report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, molecular genetics, diagnosis, and treatment patterns.
• The Beta Thalassemia Epidemiology Report and Model provide an overview of Beta Thalassemia’s risk factors and global trends in the six major markets (6MM: US, France, Germany, Italy, Spain, and the UK).
• The report provides insight into Beta Thalassemia’s historical and forecasted patient pool in six major markets covering the United States andEU5 (Germany, Spain, France, Italy, UK).
• The report helps to recognize the growth opportunities in the 6MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Beta thalassemia.
• The report provides the segmentation of the Beta Thalassemia epidemiology by Total prevalent cases of Beta Thalassemia minor in 6MM.
• The report provides the Beta Thalassemia epidemiology segmentation by the Diagnosed prevalence of Beta Thalassemia cases in 6MM.
• The report provides the Beta Thalassemia epidemiology segmentation by diagnosing Beta Thalassemia patients by disease type cases in 6MM.

Report Highlights
• 11-year Forecast of Beta Thalassemia epidemiology
• 6MM Coverage
• Total prevalent cases of Beta Thalassemia minor
• Diagnosed Prevalence of Beta Thalassemia cases
• Diagnosed Beta Thalassemia patients by disease type

KOL Views
We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
• What major factors will drive the change in the patient population in Beta Thalassemia during the forecast period (2019–2032)?
• What are the key findings of the Beta Thalassemia epidemiology across 6MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
• What would be the total number of Beta Thalassemia patients across the 6MM during the forecast period (2019–2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
• At what CAGR the patient population is expected to grow in 6MM during the forecast period (2019–2032)?
• What are the disease risk, burden, and unmet needs of Beta Thalassemia?
• What are the currently available treatments for Beta Thalassemia?

Reasons to buy
The Beta Thalassemia epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Beta Thalassemia market.
• Quantify patient populations in the global Beta Thalassemia market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Beta Thalassemia therapeutics in each market covered.
• Understand the magnitude of the Beta Thalassemia minor population by its prevalence.
• Understand the magnitude of the Beta Thalassemia population by its Diagnosed prevalence cases.
• Understand the magnitude of the Beta Thalassemia population by its Diagnosed patients of Beta Thalassemia by disease type cases.
• The Beta Thalassemia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Beta Thalassemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Study Period: 2019–2032
A recent study (Lal et al., 2021) mentions that a precise estimate of the total number of individuals with thalassemia in the US is unavailable due to the lack of either a state or national database. Surveys have shown that 10 large thalassemia centers in the country collectively follow about 1,100 patients, while additional 1,500 patients are estimated to receive care at other hospitals regions. Thus the aggregate number of patients followed at smaller centers and community practices surpass those at the major centers.
According to NHR annual report 2020, there are >900 beta thalassemia major patients and >200 beta thalassemia intermedia patients living in the UK. Similar to other North European geographies, by ethnicity, people with Pakistani ethnicity were the most (>400 patients), followed by Indian (>200) and other Asian ethnicities. Therapy-wise, around 750 thalassemia patients were on Iron Chelation therapy, and around 600 patients were on blood transfusions (NHR Report, 2020).
An Italian study estimated approximately 6,500 transfusion-dependent and 6,000 non-transfusion-dependent beta thalassemia intermedia patients in Italy (Angelucci et al., 2016). Likewise, the study published by Borchert et al. (2018) identified 623 prevalent beta thalassemia patients based on claims data analysis utilizing the InGef database. When extrapolated to the German population in 2015, these cases corresponded to 13,210 patients.